New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annu...(3 patients were randomized to receive SE...),Health

SEROQUEL XR 150 mg/day, SEROQUEL XR 300 mg/day, or placebo. At Week 6,

all SEROQUEL XR groups had significantly reduced mean MADRS score

versus placebo (-11.07): -13.56 (p<0.05) for 50 mg/day; -14.50

(p<0.001) for 150 mg/day; and -14.18 (p<0.01) for 300 mg/day. By Day

4, all SEROQUEL XR groups significantly reduced mean MADRS score versus

placebo (-3.27): -4.91 (p<0.01) for 50 mg/day; -5.43 (p<0.001) for 150

mg/day; and -5.35 (p<0.001) for 300 mg/day. The most common adverse

events (AEs) (greater than or equal to 5% and double the rate of

placebo in any SEROQUEL XR dose group) were dry mouth, sedation,

somnolence, dizziness, constipation, back pain, irritability, and

myalgia.(1)

-- Study 6 (Poster # NR3-088) -- In a six-week, multicenter, double-blind

study, 446 patients were randomized to receive antidepressant (AD) plus

SEROQUEL XR 150 mg/day, SEROQUEL XR 300 mg/day, or placebo. SEROQUEL XR

300/mg day plus an antidepressant showed statistically significant

advantage versus placebo plus an AD for 1) change in MADRS total score

at Week 6 (-14.70 versus -11.7; p<0.01); 2) improvement in MADRS from

Week 1 onwards; 3) response (58.9% versus 46.2%; p<0.05); and 4)

remission (42.5% versus 24.5%; p<0.01). For SEROQUEL XR 150 mg/day plus

AD, improvements in these variables were not significantly different

versus placebo, except for MADRS improvement at Weeks 1 and 2. The most

common adverse events (AEs) (greater than or equal to 5% and double the

rate of placebo in any SEROQUEL XR dose group) were dry mouth,

somnolence, sedation, dizziness, constipation, fatigue, and weight

increased.(3)

-- Study 5 (Poster # NR3-017) -- In a time-to-event, double-blind,

randomized-withdrawal, par
'/>"/>